NVCR

NovoCure Ltd. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website novocure.com
Employees(FY) 1320
ISIN JE00BYSS4X48

Performance

-5.39%

-2.03%

-6.75%

-23.33%

+12.93%

YTD

+38.31%

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Advanced Technical Analysis

Technical Analysis of NVCR 2024-11-20

The stock's Moving Average Score of 56 indicates a neutral to slightly bullish sentiment, while the Oscillators Score of 43 leans towards bearish, and the overall Technical Score of 50 reinforces a neutral outlook. Collectively, these scores suggest a mixed sentiment in the market, with no strong directional bias at this time.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NVCR

Stock Rank

Recent News & Updates

2024-10-31 07:30
NovoCure’s Strong Q3 and Leadership Changes in 2024(TipRanks)
2024-10-31 03:04
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...(GuruFocus.com)
2024-10-30 23:00
NovoCure (NVCR) Q3 2024 Earnings Call Transcript(Motley Fool)
2024-10-30 10:24
NovoCure Names New Chief Financial Officer(MT Newswires)
2024-10-30 09:22
NovoCure Q3 Loss Narrows, Net Revenue Increases(MT Newswires)
2024-10-30 08:15
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-10-30 07:10
NovoCure: Q3 Earnings Snapshot(Associated Press Finance)
2024-10-30 07:02
Novocure Appoints Christoph Brackmann as Chief Financial Officer(Business Wire)
2024-10-30 07:00
Novocure Reports Third Quarter 2024 Financial Results(Business Wire)
2024-10-29 19:02
Novocure Appoints Christoph Brackmann as Chief Financial Officer(Businesswire)
2024-10-29 19:00
Novocure Reports Third Quarter 2024 Financial Results(Businesswire)
2024-10-17 10:52
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment(GuruFocus.com)
2024-10-17 08:00
NovoCure scoops FDA approval on wearable for metastatic cancer treatment(Medical Device Network)
2024-10-16 20:00
NovoCure scoops FDA approval on wearable for metastatic cancer treatment(Yahoo Finance)
2024-10-16 11:57
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.(Investor's Business Daily)
2024-10-16 09:10
Sector Update: Health Care Stocks Rise Premarket Wednesday(MT Newswires)
2024-10-16 08:54
Sector Update: Health Care(MT Newswires)
2024-10-16 08:16
Novocure wins FDA approval for electric field device in lung cancer(BioPharma Dive)
2024-10-16 07:56
Top Premarket Gainers(MT Newswires)
2024-10-16 07:28
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients(Benzinga)
2024-10-16 06:46
HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24(MT Newswires)
2024-10-16 06:26
Novocure shares soar 33% as FDA approves lung cancer treatment(Investing.com)
2024-10-16 03:45
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?(Zacks)
2024-10-15 18:09
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment(Investor's Business Daily)
2024-10-15 17:05
NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours(MT Newswires)
2024-10-15 16:43
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer(Business Wire)
2024-10-15 04:43
FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer(Businesswire)
2024-10-01 07:00
Novocure to Report Third Quarter 2024 Financial Results(Business Wire)
2024-09-30 19:00
Novocure to Report Third Quarter 2024 Financial Results(Businesswire)
2024-09-09 07:00
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy(Business Wire)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.